Aileron Therapeutics, Inc. (ALRN)
NASDAQ: ALRN · Real-Time Price · USD
3.850
-0.230 (-5.64%)
At close: Oct 30, 2024, 4:00 PM
3.990
+0.140 (3.64%)
After-hours: Oct 30, 2024, 4:44 PM EDT
Aileron Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
83.41M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Coherus BioSciences | 308.13M |
Protalix BioTherapeutics | 38.05M |
CASI Pharmaceuticals | 23.10M |
BeyondSpring | 1.88M |
MediciNova | 1.00M |
InflaRx | 113.02K |
ALRN News
- 18 days ago - Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis - PRNewsWire
- 5 weeks ago - Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - PRNewsWire
- 2 months ago - Aileron Therapeutics to Present at the 8th Annual IPF Summit - PRNewsWire
- 2 months ago - Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights - PRNewsWire
- 3 months ago - Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - PRNewsWire
- 4 months ago - Aileron Therapeutics to be Included in the Russell Microcap® Index - PRNewsWire
- 6 months ago - Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 6 months ago - Aileron Therapeutics to Present at Two Upcoming Investor Conferences - GlobeNewsWire